New MS Drug Cuts Relapses Better Than Current Treatment

People living with multiple sclerosis just got a potential game changer in their fight against unpredictable disease flares.

In two major clinical trials involving about 2,000 people worldwide, an experimental oral drug called remibrutinib beat an approved therapy at reducing MS relapses. The results were strong enough that developer Novartis announced plans to seek approval globally.

Multiple sclerosis is a chronic condition where inflammation damages healthy cells in the brain and spinal cord. Most patients experience relapses, which are sudden flare-ups when symptoms worsen due to new inflammatory activity, making daily life unpredictable and challenging.

The trials, called REMODEL-1 and REMODEL-2, compared remibrutinib against Aubagio, an oral drug already approved in more than 80 countries. Over 2.5 years of follow-up, remibrutinib reduced average yearly relapse rates significantly more than the approved treatment.

Remibrutinib works by blocking an enzyme called BTK that drives certain inflammatory immune cells involved in MS. Beyond cutting relapse rates, the drug also led to fewer inflammatory lesions visible on MRI scans and showed signs of slowing disability progression.

"Despite advances in treatment, an unmet need remains for oral therapies that can deliver robust relapse prevention," said Dr. Shreeram Aradhye, chief medical officer at Novartis. The company reported safety data looked positive and aligned with earlier studies, though detailed results will be presented at a scientific conference in October.

The Bright Side

This breakthrough matters because it gives people with MS more options. While several disease-modifying therapies exist, each has different trade-offs between effectiveness, safety, and convenience.

An oral medication that's both highly effective and well-tolerated could mean fewer hospital visits, more predictable symptom management, and better quality of life. For patients who've struggled to find the right treatment, remibrutinib represents renewed hope.

The drug belongs to a class called BTK inhibitors, which other companies have also tested for MS with mixed results. Genentech's version beat Aubagio in trials, while Sanofi's did not, making remibrutinib's success particularly encouraging.

If approved, patients worldwide could have access to this treatment within the next year or two. After decades of limited options, the MS treatment landscape keeps expanding with genuinely better choices.